Ceryvyn Therapeutics Limited (UKJ2) Ratios
Ceryvyn Therapeutics Limited Ratios
DE:UKJ2's free cash flow for Q4 2024 was $-137.45M. For the 2024 fiscal year, DE:UKJ2's free cash flow was increased by ― and operating cash flow was $-137.41M. See a summary of the company’s cash flow.
| Ratios | Jun 24 | Jun 23 | Jun 22 | Jun 21 | Jun 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.94 | 5.25 | 4.98 | 44.46 | 10.31 |
| Quick Ratio | 2.94 | 5.25 | 4.98 | 44.46 | 10.31 |
| Cash Ratio | 2.69 | 4.76 | 3.71 | 38.05 | 8.96 |
| Solvency Ratio | -0.83 | -1.35 | -7.29 | -14.58 | -2.26 |
| Operating Cash Flow Ratio | -2.51 | -6.37 | -5.62 | -14.76 | -1.19 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -76.41M | $ -9.18M | $ 69.57M | $ 179.81M | $ 64.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -1.87 | -0.03 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 2.15 | -0.03 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 2.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.49 | -16.85 | 1.25 | 1.02 | 1.11 |
| Debt Service Coverage Ratio | -6.30 | -10.72 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -6.34 | -11.16 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.15 | 0.04 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.15 | 0.60 | 0.49 | 2.98 | 2.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 17.42% | -55.42% | -85.91% | -521.85% | -254.54% |
| EBIT Margin | -159940.37% | -124518.33% | -79263.52% | -54667.10% | -16929.71% |
| EBITDA Margin | -160443.72% | -138554.61% | -106489.56% | -57455.77% | -17079.20% |
| Operating Profit Margin | -153885.37% | -138647.99% | -106575.99% | -57815.66% | -16929.71% |
| Pretax Profit Margin | -184215.67% | -136936.62% | -109300.18% | -73285.73% | -16716.71% |
| Net Profit Margin | -176665.73% | -131469.80% | -102353.69% | -66087.58% | -11047.04% |
| Continuous Operations Profit Margin | -176665.73% | -131469.80% | -102353.69% | -66087.58% | -11329.26% |
| Net Income Per EBT | 95.90% | 96.01% | 93.64% | 90.18% | 66.08% |
| EBT Per EBIT | 119.71% | 98.77% | 102.56% | 126.76% | 98.74% |
| Return on Assets (ROA) | -116.66% | -142.98% | -146.57% | -32.97% | -22.42% |
| Return on Equity (ROE) | 290.52% | 2409.60% | -183.45% | -33.73% | -24.87% |
| Return on Capital Employed (ROCE) | -153.80% | -186.16% | -190.90% | -29.51% | -38.02% |
| Return on Invested Capital (ROIC) | -147.39% | -178.58% | -178.77% | -26.59% | -50.84% |
| Return on Tangible Assets | -116.66% | -142.98% | -146.57% | -32.97% | -22.42% |
| Earnings Yield | -145.30% | -128.92% | -43.58% | -18.02% | -2.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.02 | 0.00 | 0.00 | 0.02 |
| Payables Turnover | 0.00 | 0.01 | 0.02 | 0.24 | 0.13 |
| Inventory Turnover | 0.00 | 250472.00 | 0.00 | 571982.00 | 0.00 |
| Fixed Asset Turnover | 0.94 | 0.53 | 3.06 | 0.59 | 0.52 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -100323.09 | -11138.05 | -17902.56 | -1542.82 | 19198.42 |
| Days of Sales Outstanding | 34619.87 | 14863.61 | 0.00 | 0.00 | 22059.05 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 134942.96 | 26001.66 | 17902.56 | 1542.82 | 2860.62 |
| Operating Cycle | 34619.87 | 14863.61 | 0.00 | 0.00 | 22059.05 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.02 | -0.38 | -0.26 | -0.18 | -0.03 |
| Free Cash Flow Per Share | -2.02 | -0.38 | -0.26 | -0.18 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | -4808.01 | -5493.72 | -4218.69 | -3585.76 | -2247.97 |
| Capital Expenditure Coverage Ratio | -4808.01 | -5493.72 | -4218.69 | -3585.76 | -2247.97 |
| Operating Cash Flow Coverage Ratio | -1.14 | -656.83 | 0.00 | -405.79 | -31.10 |
| Operating Cash Flow to Sales Ratio | -1291.57 | -1112.56 | -786.64 | -663.82 | -56.51 |
| Free Cash Flow Yield | -106.25% | -13.64% | -4.19% | -2.26% | -0.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.69 | -0.78 | -2.29 | -5.55 | -35.99 |
| Price-to-Sales (P/S) Ratio | 1215.83 | 1019.74 | 2348.64 | 3667.83 | 3976.35 |
| Price-to-Book (P/B) Ratio | -2.00 | -18.69 | 4.21 | 1.87 | 8.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.94 | -0.92 | -2.98 | -5.52 | -70.34 |
| Price-to-Operating Cash Flow Ratio | -0.94 | -0.92 | -2.99 | -5.53 | -70.37 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.02 | -0.03 | -0.03 | 1.16 |
| Enterprise Value Multiple | -0.60 | -0.14 | -1.72 | -3.41 | -20.80 |
| Enterprise Value | 120.75M | 1.18B | 2.28B | 2.54B | 4.58B |
| EV to EBITDA | -0.60 | -5.29 | -17.16 | -48.09 | -183.78 |
| EV to Sales | 968.58 | 7328.27 | 18270.12 | 27632.72 | 31387.50 |
| EV to Free Cash Flow | -0.75 | -6.59 | -23.22 | -41.62 | -555.22 |
| EV to Operating Cash Flow | -0.75 | -6.59 | -23.23 | -41.63 | -555.47 |
| Tangible Book Value Per Share | -0.95 | -0.02 | 0.19 | 0.53 | 0.25 |
| Shareholders’ Equity Per Share | -0.95 | -0.02 | 0.19 | 0.53 | 0.25 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | 0.04 | 0.06 | 0.10 | -0.34 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.76 | -0.45 | -0.34 | -0.18 | -0.06 |
| Tax Burden | 0.96 | 0.96 | 0.94 | 0.90 | 0.66 |
| Interest Burden | 1.15 | 1.10 | 1.38 | 1.34 | 0.99 |
| Research & Development to Revenue | 1414.39 | 1126.58 | 867.35 | 377.36 | 119.81 |
| SG&A to Revenue | 124.24 | 119.57 | 130.39 | 129.14 | 45.30 |
| Stock-Based Compensation to Revenue | 40.79 | 36.20 | 42.00 | 42.37 | 5.02 |
| Income Quality | 0.73 | 0.85 | 0.77 | 1.00 | 0.51 |
Currency in AUD
